Company intelligence / Profile preview

Dizal Pharmaceutical Co., Ltd.

Jiangsu, China

Ownership: Private
Employees: ~581
Development stage: Preclinical

Overview

Dizal Pharmaceutical has two approved drugs: Sunvozertinib (approved in China on August 22, 2023) for EGFR ex20ins mutation in non-small cell lung cancer, and Golidocitinib (approved in China on June 18, 2024) for Peripheral T-Cell Lymphoma. The company also has several other candidates in clinical development, including DZD-8586 in Phase 1/2 for B-cell lymphoma.

Therapeutic areas: OncologyImmunology
Modalities: Small molecule drugsChemical drugs
Industry: Biotech

Drug pipeline

7 assets

sunvozertinib

Approved

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Dizal Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dizal Pharmaceutical Co., Ltd..

Explore the full profile